Your Directors have pleasure in presenting the 53rd Annual Report and Audited Senior Joint Commissioner,. Kolkata. Delhi Value Added Tax. Ranbaxy Laboratories Limited Annual Report CHAIRMAN’S MESSAGE Down Inc. Germany (upto 16 December ) 11 Ranbaxy Unichem Co. Get Ranbaxy Laboratories latest Balance Sheet, Financial Statements and Ranbaxy Laboratories detailed profit and loss accounts.

Author: Galrajas Gat
Country: Dominica
Language: English (Spanish)
Genre: Finance
Published (Last): 18 September 2011
Pages: 69
PDF File Size: 14.2 Mb
ePub File Size: 2.22 Mb
ISBN: 435-9-45938-852-9
Downloads: 99553
Price: Free* [*Free Regsitration Required]
Uploader: Shaktilmaran

It also includes a demand of Rs. Pending disposal of the matter, the management considers the impact as unascertainable. The Company has also issued redeemable non-convertible debentures which are listed for trading on the NSE in India.

The options vests evenly over a period of three years from the date of grant. The amount is excluding interest and penalty, if any.

Annual Reports & Presentations

The options vests evenly over a period of fve years from the date of grant. Quick Links for ranbaxylaboratories. The Company has challenged the order before the Hon”ble Income Tax Appellate Tribunal ITAT and pending disposal of the matter, the management considers the amount of tax liability as unascertainable.

Options are granted at the discretion of the committee to selected employees depending upon certain criterion. A, Italy Ranbaxy Malaysia Sdn.

Thank you for your kind understanding. The Company has not accepted the same and has fled its objections before the DRP. These derivatives are annuao used for trading or speculation purposes. We are attempting to resolve this funny technical issue!

Please do reach out to us at contactus reportjunction. ESOS I and II provide that the grant price of options is to be determined at the average of the daily closing price of the Company”s equity shares on the NSE during a period of 26 weeks preceding the date of the grant.

The amount recognised in the Statement of Proft and Loss represents consequential cost sales return, inventory write off and customer claim recognised by the Company.

Ranbaxy UK Limited, U. Contingent liabilities and commitments to the extent not 20110-11 for As at As at 31 March 31 December Contingent liabilities i Guarantees a Letter of comfort on behalf of subsidiaries, to the extent of limits 6, Relort, the Company has deposited Rs. Options lapse, if they are not exercised prior to the expiry date, which is ten years from the date of grant.


Segment information In accordance with AS 17, Segment Reporting, segment information has been given in the consolidated fnancial statements of the Company, and therefore, no separate disclosure on segment information is given ranhaxy these fnancial statements.

Ranbaxy Laboratories

Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol. ESOS provides that the grant price of options will be the latest available closing price on the stock exchange on which the shares of the Company are listed, prior to the date of the meeting of the Committee in which the options are granted.

Description cannot exceed characters. It is the largest exporter of bulk drugs and pharmaceutical dosag. The Company expects to resume API bulk shipments to EU countries from Toansa manufacturing facility upon receipt of clearances from relevant regulatory authorities. Company overview Ranbaxy Laboratories Limited ”the Company” together with its subsidiaries and associates, operates as an integrated international pharmaceutical organisation with businesses encompassing the entire value chain in the marketing, production and distribution of repoft products.

Please do try to use an alternate pdf reader in case the file is unopenable with adobe. Clicking on the download link annkal add the report to your downloaded reports. Nifty bounces over ; Bharti languishes 17 Feb 10 Options lapse, if they are not exercised prior to the expiry date, which is three months from the date of the vesting.

Erport markets of US, Europe not so promising 27 Oct 09 This scheme limits the maximum grant of options to an employee or a director at 30, in any given year. Pursuant to the transaction, the Company has recorded a gain of Rs.

Ranbaxy Laboratories Balance Sheet, Ranbaxy Laboratories Financial Statement & Accounts

As per the Scheme, the share exchange ratio has been proposed as 0. Foreign funds hint at hiking India allocation 25 Mar 10 The Company will issue shares to the Trust which will allocate the shares to the respective employees upon exercise of stock options from time to time under ESOP – The amount above represents the difference payable. Hedging and derivatives a The Company uses various forms of derivative instruments such as foreign exchange forward contracts including instruments which are in substance forward contractsoptions, currency swaps, currency cum interest rate swaps and interest rate swaps to hedge its exposure to movements in foreign exchange and interest rates.


If the shares are listed on more than one stock exchange, then the stock exchange where there is highest trading volume on the said date shall be considered.

Consequently, stock write off and other costs of Rs. Due to the nature of these disputes and also in view of signifcant uncertainty of outcome, the Company believes that the amount of exposure cannot be currently determinable.

The effective portion of such cash fow hedges was recorded as part of reserves and surplus within hedging reserve and re-classifed in the Statement of Proft and Loss in the period corresponding to the occurrence of the highly probable forecasted transactions.

You will be able to download it at any time during the subscription period. ESOP – provides that reoort grant price will be the face value of the equity share. The ineffectiveness arising from cash fow hedges which was recognised in Statement of Proft and Loss was not material.

However, considering the above matters relating to the Toansa manufacturing facility, provisions primarily relating to inventories, trade commitments, sales return etc. Ranbaxy gets approval from Japan for Dewas unit; stk up 24 Jul 09 The Company received the fnal assessment order from the AO in Repor whereby demand of Rs